I te 24 o Ākuhata, 2022, i whakaaetia e te US Food and Drug Administration (FDA) te ibrutinib hei rongoā mō ngā tūroro tamariki neke atu i te 1 tau te pakeke me te mate graft-versus-host mau tonu (cGVHD) e whiwhi ana i muri i te korenga o te rongoā pūnaha 1-, maha-rārangi rānei. Ko te tohu kua whakaaetia ko te nuinga mō ngā tūroro tamariki, me te reiti urupare whānui o te 60% i te wiki 25, ā, ko ngā hanganga rongoā kei roto ko ngā kāpūru, ngā papa me ngā whakatārewatanga ā-waha.
Ko Ibrutinib, he aukati BTK i whakawhanakehia tahitia e Pharmacyclics/Johnson & Johnson, he aukati kinase kua whakaaetia i mua mo te maimoatanga o te mate pukupuku toto lymphocytic mau tonu me te lymphoma pūtau me etahi atu mate.
Ko te arotahi a Suntech ki te whakawhanake me te whakaputa i ngā takawaenga rongoā me ngā API mā te whakamahi i te hangarau matomato. I tēnei wā, e toru ngā hua takawaenga o te ibrutinib kua whakawhanakehia e tā mātou kamupene, tae atu ki te C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, ā, kua hokohokohia katoatia ēnei i roto i ngā wheketere GMP. I roto i ēnei, ko te takawaenga o te C AS: 143900-44-1 ka hangaia mā te hangarau matū-enzymatic, he pai ki a ia te tiaki taiao matomato, te utu iti me te kounga teitei. Nau mai ki te kōrero me te mahi tahi!
Wā tuku: Whiringa-ā-rangi-04-2022